REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

I. Chau, A.F.C. Okines, D.G. de Castro, C. Saffery, Y. Barbachano, A. Wotherspoon, L. Puckey, S.H. Wilson, F.Y. Coxon, G.W. Middleton, D.R. Ferry, T.D.L. Crosby, S. Madhusudan, J. Wadsley, J.S. Waters, M. Hall, D. Swinson, A. Robinson, D. Smith, D. CunninghamU.K.N.C.R.I.U. Gastro

Research output: Contribution to journalArticlepeer-review

Cite this